Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$113.86 USD

113.86
331,957

0.00 (0.00%)

Updated Oct 8, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.

Roche Submits sBLA to FDA for Label Expansion of Kadcyla

Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

What's in the Cards for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.

Mylan's Generic Version of Advair Diskus Wins FDA Approval

Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance

Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y

Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.

Novartis Misses Earnings and Sales Estimates in Q4

Novartis (NVS) missed estimates both for earnings and sales in the fourth quarter of 2018.

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings?

Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.

Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.

Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

NVS or AZN: Which Is the Better Value Stock Right Now?

NVS vs. AZN: Which Stock Is the Better Value Option?

Intrexon Signs Licensing Agreement with Next Green Wave

Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off

Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.

6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

Tilray Shares Rally as Investor Plans Not to Sell Shares

Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.

NASH Space in Focus in 2019 as Firms Look to Diversify

NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why

Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.